NutriBand Secures $5M Non-Convertible Credit Line Extension for Fentanyl Patch Commercialization
NTRB is trading near its 52-week low of $2.9 (12% above the low) on elevated volume (2.8× avg).
Summary
NutriBand Inc. secured a $5 million non-convertible credit line extension, providing vital funding for the FDA approval and commercialization of its lead abuse-deterrent fentanyl patch.
Key Events · Financing and Capital Events · NTRB
-
Credit Line Extension Formalized
NutriBand Inc. entered into an amended three-year $5,000,000 credit line facility on June 1, 2026, replacing a previous facility that was scheduled to expire on July 13, 2026. The new facility matures on July 1, 2029.
-
Non-Dilutive Financing
The credit line bears interest at 7% per annum and does not permit conversion by the lender of outstanding amounts into common stock, avoiding direct equity dilution for existing shareholders.
-
Strategic Funding for Lead Product
Proceeds from the credit line are specifically designated to finance the FDA approval process and commercial scale manufacturing for the company's patented lead product, AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system.
-
Addresses Financial Concerns
This formal agreement provides crucial capital, extending the company's financial runway and addressing 'going concern doubts' that were noted in the recent Q1 2026 10-Q filing.
Analysis · NTRB · Industrial Applications And Services
NutriBand Inc. has formalized a three-year extension of its $5 million credit line, crucial for funding the FDA approval process and commercial manufacturing of its AVERSA™ Fentanyl patch. This non-convertible debt facility provides essential capital without immediate shareholder dilution, addressing prior financial concerns and extending the company's operational runway through a critical development phase. This follows the company's Q1 2026 10-Q filing on June 11, 2026, which first mentioned the credit line extension and its role in alleviating going concern doubts.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NTRB was trading at $3.24 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $35.3M. The 52-week trading range was $2.90 to $11.68. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.